Relative androgen excess during the menopausal transition predicts incident metabolic syndrome in midlife women: Study of Women's Health Across the Nation

Menopause

Volumn 16, Issue 2, 2009, Pages 257-264

  Torréns, Javier I ^a,e   Sutton Tyrrell, Kim ^b   Zhao, Xinhua ^b   Matthews, Karen ^b   Brockwell, Sarah ^b   Sowers, MaryFran ^c   Santoro, Nanette ^d  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^e Medical Diagnostic Associates   (United States)

Author keywords

Estrogen; Menopause; Metabolic syndrome; Testosterone

Indexed keywords

ANDROGEN; ESTROGEN; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE;

ADULT; ARTICLE; CLIMACTERIUM; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; METABOLIC SYNDROME X; MORBIDITY; PREMENOPAUSE; RISK FACTOR;

ESTRADIOL; FEMALE; HUMANS; INCIDENCE; METABOLIC SYNDROME X; MIDDLE AGED; PERIMENOPAUSE; PREDICTIVE VALUE OF TESTS; SEX HORMONE-BINDING GLOBULIN; TESTOSTERONE; WOMEN'S HEALTH;

EID: 67349245602     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/gme.0b013e318185e249     Document Type: Article

References (47)

1. Grady D, Herrington D, Bittner V, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II) [published correction appears in JAMA. 2002;288:1064]. JAMA 2002;288:49-57.
2. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
3. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004; 291:1701-1712.
4. Oh JY, Barrett-Connor E, Wedick NM, Wingard DL, Rancho Bernardo Study. Endogenous sex hormones and the development of type 2 diabetes in older men and women: the Rancho Bernardo study. Diabetes Care 2002;25:55-60.
5. Haffner SM, Valdez RA. Endogenous sex hormones: impact on lipids, lipoproteins, and insulin. Am J Med 1995;98:40S-47S.
6. Pugeat M, Moulin P, Cousin P, et al. Interrelations between sex hormone-binding globulin (SHBG), plasma lipoproteins and cardiovascular risk. J Steroid Biochem Mol Biol 1995;53:567-572.
7. Haffner SM, Valdez RA, Morales PA, et al. Decreased sex hormoneY binding globulin predicts noninsulin-dependent diabetes mellitus in women but not in men. J Clin Endocrinol Metab 1993;77:56-60.
8. Goodman-Gruen D, Barrett-Connor E. Sex hormone-binding globulin and glucose tolerance in postmenopausal women. The Rancho Bernardo Study. Diabetes Care 1997;20:645-649.
9. Mudali S, Dobs AS, Ding J, Cauley JA, Szklo M, Golden SH. Endogenous postmenopausal hormones and serum lipids: the atherosclerosis risk in communities study. J Clin Endocrinol Metab 2005;90: 1202-1209.
10. Golden SH, Ding J, Szklo M, Schmidt MI, Duncan BB, Dobs A. Glucose and insulin components of the metabolic syndrome are associated with hyperandrogenism in postmenopausal women: the atherosclerosis risk in communities study. Am J Epidemiol 2004; 160:540-548.
11. Rexrode KM, Manson JE, Lee IM, et al. Sex hormone levels and risk of cardiovascular events in postmenopausal women. Circulation 2003;108: 1688-1693.
12. Weinberg ME, Manson JE, Buring JE, et al. Low sex-hormone binding globulin is associated with the metabolic syndrome in postmenopausal women. Metabolism 2006;55:1473-1480.
13. Burger HG, Dudley EC, Cui J, Dennerstein L, Hopper JL. A prospective longitudinal study of serum testosterone, dehydroepiandrosterone sul- fate, and sex hormone-binding globulin levels through the menopause transition. J Clin Endocrinol Metab 2000;85:2832-2838.
14. Longcope C, Franz C, Morello C, Baker R, Johnston CC Jr. Steroid and gonadotropin levels in women during the peri-menopausal years. Maturitas 1986;8:189-196.
15. Rannevik G, Jeppsson S, Johnell O, Bjerre B, Laurell-Borulf Y, Svanberg L. A longitudinal study of the perimenopausal transition: altered profiles of steroid and pituitary hormones, SHBG and bone mineral density. Maturitas 1995;2:103-113.
16. Malik S, Wong ND, Franklin SS, et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 2004;110:1245-1250.
17. Lempiainen P, Mykkanen L, Pyorala K, Laakso M, Kuusisto J. Insulin resistance syndrome predicts coronary heart disease events in elderly nondiabetic men. Circulation 1999;100:123-128.
18. Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24:683-689.
19. Bonora E, Kiechl S, Willeit J, et al. Carotid atherosclerosis and coronary heart disease in the metabolic syndrome: prospective data from the Bruneck study. Diabetes Care 2003;26:1251-1257.
20. Sowers MF, Crawford SL, Sternfeld B, et al. SWAN: a multi-center, multi-ethnic, community-based cohort study of women and the menopausal transition. In: Lobo RA, Kelsey J, Marcus R, eds. Menopause: Biology and Pathobiology. San Diego, CA: Academic Press, 2000:175-188.
21. Block G, Hartman AM, Dresser CM, Carroll MD, Gannon J, Gardner L. A data-based approach to diet questionnaire design and testing. Am J Epidemiol 1986;124:453-469.
22. Huang MH, Harrison GG, Mohamed MM, et al. Assessing the accuracy of a food frequency questionnaire for estimating usual intake of phytoestrogens. Nutr Cancer 2000;37:145-154.
23. Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 1999;84:3666-3672.
24. WHO, International Obesity Task Force, International Association for the Study of Obesity. The Asian-Pacific Perspective: Redefining Obesity and its Treatment. Sydney, Australia: Health Communications, 2000.
25. Grundy SM, Cleeman JI, Daniels SR, et al; American Heart Association; National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation 2005; 112:2735-2752.
26. Deurenberg-Yap M, Yan TB, Kai CS, Deurenberg P, Van Staveren WA. Manifestation of cardiovascular risk factors at low levels of body mass index and waist-to-hip ratio in Singaporean Chinese. Asia Pac J Clin Nutr 1999;80:323-330.
27. Ko GT, Chan JC, Cockram CS, Woo J. Prediction of hypertension, diabetes, dyslipidaemia or albuminuria using simple anthropometric indexes in Hong Kong Chinese. Int J Obes Relat Metab Disord 1999;23: 1136-1142.
28. Prentice RL, Gloeckler A. Regression analysis of grouped survival data with application to breast cancer data. Biometrics 1978;34:57-67.
29. Allison PD. Survival Analysis Using the SAS System: A Practical Guide. Cary, NC: SAS Institute Inc, 1995.
30. Hosmer DW, Lemeshow S. Applied Logistic Regression. New York, NY: John Wiley & Sons, Inc, 1989.
31. Braunstein GD. Androgen insufficiency in women: summary of critical issues. Fertil Steril 2002;77(suppl 4):S94-S99.
32. Polderman KH, Gooren LJ, Asscheman H, Bakker A, Heine RJ. Induction of insulin resistance by androgens and estrogens. J Clin Endocrinol Metab 1994;79:265-271.
33. Diamond MP, Grainger D, Diamond MC, Sherwin RS, Defronzo RA. Effects of methyltestosterone on insulin secretion and sensitivity in women. J Clin Endocrinol Metab 1998;83:4420-4425.
34. Buster JE, Kingsberg SA, Aguiree O, et al. Testosterone patch for low sexual desire in surgically menopausal women: a randomized trial. Obstet Gynecol 2005; 105:944-952.
35. Simon J, Braunstein G, Nachtigall L, et al. Testosterone patch increases sexual activity and desire in surgically menopausal women with hypoactive sexual desire disorder. J Clin Endocrinol Metab 2005;90: 5226-5233.
36. Sutton-Tyrrell K, Wildman RP, Matthews KA, et al. Sex hormone binding globulin and the free androgen index are related to CV risk factors in multi-ethnic pre and peri-menopausal women enrolled in the Study of Women's Health Across the Nation (SWAN). Circulation 2005;111:1242-1249.
37. Sowers M, Derby C, Jannausch ML, Torrens JI, Pasternak R. Insulin resistance, hemostatic factors, and hormone interactions in pre- and perimenopausal women: SWAN. J Clin Endocrinol Metab 2003;88: 4904-4910.
38. Guthrie JR, Taffe JR, Lehert P, Burger HG, Dennerstein L. Association between hormonal changes at menopause and the risk of a coronary event: a longitudinal study. Menopause 2004; 11:315-322.
39. Bild DE, Detrano R, Peterson D, et al. Ethnic differences in coronary calcification: the Multi-Ethnic Study of Atherosclerosis (MESA). Circulation 2005;111:1313-1320.
40. Krietmann B, Bayard F. Androgen interaction with oestrogen receptor in human tissues. J Steroid Biochem 1979;11:1589-1595.
41. Poulin R, Simard J, Labrie C, et al. Down-regulation of estrogen receptors by androgens in the ZR-75-1 human breast cancer cell line. Endocrinology 1989;125:392-399.
42. Tetsuka M, Hillier SG. Androgen receptor gene expression in rat granulosa cells: the role of follicle-stimulating hormone and steroid hormones. Endocrinology 1996; 137:4392-4397.
43. Adesanya-Famuyiwa OO, Zhou J, Wu G, Bondy C. Localization and sex steroid regulation of androgen receptor gene expression in rhesus monkey uterus. Obstet Gynecol 1999;93:265-270.
44. Panet-Raymond V, Gottlieb B, Beitel LK, Pinsky L, Trifiro MA. Interactions between androgen and estrogen receptors and the effects on their transactivational properties. Mol Cell Endocrinol 2000;167:139-150.
45. Lapidus L, Lindstedt G, Lundberg PA, Bengtsson C, Gredmark T. Concentrations of sex-hormone binding globulin and corticosteroid binding globulin in serum in relation to cardiovascular risk factors and to 12-year incidence of cardiovascular disease and overall mortality in postmenopausal women. Clin Chem 1986;32:146-152.
46. Reinecke H, Bogdanski J, Woltering A, et al. Relation of serum levels of sex hormone binding globulin to coronary heart disease in postmenopausal women. Am J Cardiol 2002;90:364-368.
47. Cameron DR, Braunstein GD. Androgen replacement therapy in women. Fertil Steril 2004;82:273-289.